영국의 의료 관련 소포 라스트 마일 배송 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the United Kingdom healthcare parcel last-mile delivery market size was valued at USD 1.30 billion in 2025 and is estimated to grow from USD 1.38 billion in 2026 to reach USD 1.86 billion by 2031, at a CAGR of 6.12% during the forecast period (2026-2031).

Growth in the United Kingdom healthcare parcel last-mile delivery market reflects a steady shift away from centralized dispensing toward parcel-led distribution that reaches patients at home, in pharmacies, and in care settings with tighter service requirements. This report is Segmented by Delivery Type (Standard, Same-Day, Next-Day), by Temperature Type (Temperature Type, Non-Temperature Controlled), by Product Type (Pharmaceuticals, Vaccines, and More), by Delivery Model (B2C, B2B), by End User (E-Pharmacies, Hospitals, and More), and by Geography (England, Scotland, and More). The Market Forecasts are Provided in Terms of Value (USD).

United Kingdom Healthcare Parcel Last-mile Delivery Market Trends and Insights

Rising Same-Day and Next-Day Demand for Time-Critical Healthcare Parcels

Urgency in regulated dispensing means that same-day and next-day delivery are increasingly treated as core service tiers in the United Kingdom healthcare parcel last-mile delivery market rather than premium add-ons. This shift is reinforced by digital prescription visibility, as the NHS App prescription tracker launched in 2025 and covered around 1,650 pharmacies, including every Boots store in England, which raises expectations for clearer parcel status and tighter delivery windows. Large prescription volumes also support this service need, as England's community pharmacies dispensed nearly 1.2 billion items in FY 2025, leaving a broad base of routine and urgent shipments moving through pharmacy and patient channels. As a result, operators in the United Kingdom healthcare parcel last-mile delivery market that can maintain tighter cut-off times, provide live visibility, and handle exceptions more effectively are better placed to win recurring healthcare flows. The effect is most visible first in urban areas, but the service standard set there tends to shape procurement expectations across the wider market.

Expansion of Home-Based Care and Direct-to-Patient Delivery

Home-based care is becoming a larger operating model for the United Kingdom healthcare parcel last-mile delivery market, as NHS-linked care pathways increasingly rely on treatment outside hospital settings. Clinical home care can reduce unnecessary hospital visits, free up acute care capacity, and maintain comparable outcomes, supporting a broader shift toward home delivery and coordinated patient services. Each shift from site-based dispensing to home care creates a more recurring parcel relationship that often needs scheduling discipline, patient communication, and, in some cases, nurse-coordinated delivery windows. That changes the role of parcel operators from simple transport vendors to service partners that help maintain treatment continuity in the United Kingdom healthcare parcel last-mile delivery market. It also supports stronger long-run demand because once a patient is enrolled in a home-based pathway, delivery becomes part of an ongoing care routine rather than a one-time shipment.

Last-Mile Cost Inflation in Low-Drop Density Healthcare Routes

Low-density delivery routes remain a meaningful brake on the United Kingdom healthcare parcel last-mile delivery market because regulated healthcare parcels are harder to consolidate than standard e-commerce volumes. Deliveries often require stronger identity checks, tighter timing, and, in some cases, controlled-temperature conditions, which limit the use of cheaper drop models and flexible consolidation points. That burden is more visible in rural England, Wales, Northern Ireland, and parts of Scotland, where travel time per successful healthcare drop tends to be structurally higher. The result is a margin gap in the United Kingdom healthcare parcel last-mile delivery market between dense urban routes, which can support faster service, and remote routes, which require greater operational effort per parcel. Unless those routes gain better commissioning support or denser healthcare demand, cost inflation is likely to remain a persistent commercial pressure.

Other drivers and restraints analyzed in the detailed report include:

1. Cold Chain Compliance Pressure Across Clinical and Pharmaceutical Parcels
2. NHS and Private Provider Outsourcing of Non-Core Logistics
3. Chain-of-Custody Risk in Multi-Hand-Off Healthcare Deliveries

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Next-day delivery held 42% of the United Kingdom healthcare parcel last-mile delivery market share in 2025, making it the largest delivery type, as overnight replenishment still aligns with the operating rhythms of wholesalers, pharmacies, and NHS-linked ordering cycles. In the United Kingdom healthcare parcel last-mile delivery market, next-day services remain the practical middle ground between routine scheduled supply and urgent point-to-point dispatch. This segment benefits from predictable routing, repeat-delivery patterns, and a broad base of ambient and regulated healthcare products that require reliable delivery without incurring full emergency costs. It also remains important because many healthcare buyers still balance service quality with procurement discipline, and next-day networks are well placed to do that at scale.

Same-day delivery is the fastest-growing segment, and it is projected to expand at a 10.20% CAGR through 2031. The strongest signal behind that shift came in April 2026, when Matternet launched NHS drone operations in Central London to move diagnostic samples, laboratory specimens, and pharmaceuticals between 2 major hospital campuses in minutes. This does not remove the role of road-based couriers, but it shows that high-acuity healthcare demand is moving toward shorter delivery windows and more specialized route design.

Non-temperature-controlled parcels accounted for 51.26% of the United Kingdom healthcare parcel last-mile delivery market size in 2025, making them the largest temperature segment, as high-volume ambient medicines, devices, and home healthcare supplies still represent the broadest parcel base. Much of this flow depends on reliability, timing, and parcel visibility rather than advanced thermal infrastructure. The segment also benefits from easier route planning and lower handling complexity compared with chilled or cryogenic transport.

Temperature-controlled delivery is smaller in volume, but the United Kingdom healthcare parcel last-mile delivery market for this segment is forecast to grow at a 6.98% CAGR through 2031 as biologics, biosimilars, and advanced therapies claim a larger share of healthcare logistics demand. FedEx strengthened this part of the market in 2025 through its IATA CEIV Pharma corporate certificate, which extended certified handling to more than 90% of its global healthcare volume. Kuehne+Nagel expanded its own-controlled network in June 2026, improving reliability for time-sensitive pharmaceutical cargo moving through European gateways, supporting the United Kingdom's supply chains.

Complete Report Scope:

• By Delivery Type
  • Standard Delivery
  • Same-Day Delivery
  • Next-Day Delivery
• By Temperature Type
  • Temperature Controlled
  • Non-Temperature Controlled
• By Product Type
  • Pharmaceuticals
    • Prescription and Specialty Drugs
    • OTC Drugs
  • Biopharmaceuticals (Biologics and Biosimilars)
  • Vaccines
  • Clinical Trial Materials
  • Cell and Gene Therapies
  • Medical Devices
  • Veterinary Medicine
  • Blood, Plasma and Blood Components
  • Diagnostic and Laboratory Products
  • Home Healthcare Supplies
  • Others
• By Delivery Model
  • B2C
  • B2B
• By End User
  • Hospitals and Clinics
  • E-Pharmacies and Pharmacies
  • Diagnostic Laboratories
  • Home Healthcare Providers
  • Direct-to-Patient Deliveries
  • Others
• By Geography
  • England
  • Scotland
  • Wales
  • Northern Ireland

List of Companies Covered in this Report:

1. Sciensus
2. Yusen Logistics Group (including Movianto)
3. Life Couriers UK Limited
4. Phoenix Healthcare Distribution
5. AAH Pharmaceuticals
6. DHL Group
7. UPS
8. Oximio
9. GXO Logistics, Inc.
10. Royal Mail Group
11. Polar Speed
12. CitySprint
13. Cencora
14. FedEx
15. DPDgroup
16. Uniphar Logistics UK
17. Geopost
18. Matternet, Inc.
19. CEVA Logistics
20. Kuehne+Nagel
21. EMED Group
22. BAP Pharma Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview and Role of Parcel Last-Mile Delivery in Healthcare Logistics
• 4.2 Healthcare Spending Trends
• 4.3 Market Drivers
  • 4.3.1 Rising Same-Day and Next-Day Demand for Time-Critical Healthcare Parcels
  • 4.3.2 Expansion of Home-Based Care and Direct-to-Patient Delivery
  • 4.3.3 Cold Chain Compliance Pressure Across Clinical and Pharmaceutical Parcels
  • 4.3.4 NHS and Private Provider Outsourcing of Non-Core Logistics
  • 4.3.5 Higher Parcel Traceability Expectations for Regulated Healthcare Shipments
  • 4.3.6 Growing Cross-Channel Fulfillment by E-Pharmacies and Omnichannel Pharmacies
• 4.4 Market Restraints
  • 4.4.1 Last-Mile Cost Inflation in Low-Drop Density Healthcare Routes
  • 4.4.2 Chain-of-Custody Risk in Multi-Hand-Off Healthcare Deliveries
  • 4.4.3 Packaging and Temperature Excursion Losses for Sensitive Parcels
  • 4.4.4 Fragmented Service Requirements Across NHS, Private, and Consumer-Directed Deliveries
• 4.5 Regulatory Framework
• 4.6 Value Chain and Distribution Channel Architecture Analysis
• 4.7 Technology Innovations Outlook
• 4.8 Porter's Five Forces Analysis
  • 4.8.1 Threat of New Entrants
  • 4.8.2 Bargaining Power of Suppliers
  • 4.8.3 Bargaining Power of Buyers
  • 4.8.4 Threat of Substitutes
  • 4.8.5 Rivalry Among Competitors
• 4.9 Evolution of Healthcare Parcel Last-Mile Delivery Requirements
• 4.10 Impact of Geo-Political Events on Supply Chain Shifts

5 Market Size and Growth Forecasts (Value, 2026-2031)

• 5.1 By Delivery Type
  • 5.1.1 Standard Delivery
  • 5.1.2 Same-Day Delivery
  • 5.1.3 Next-Day Delivery
• 5.2 By Temperature Type
  • 5.2.1 Temperature Controlled
  • 5.2.2 Non-Temperature Controlled
• 5.3 By Product Type
  • 5.3.1 Pharmaceuticals
    • 5.3.1.1 Prescription and Specialty Drugs
    • 5.3.1.2 OTC Drugs
  • 5.3.2 Biopharmaceuticals (Biologics and Biosimilars)
  • 5.3.3 Vaccines
  • 5.3.4 Clinical Trial Materials
  • 5.3.5 Cell and Gene Therapies
  • 5.3.6 Medical Devices
  • 5.3.7 Veterinary Medicine
  • 5.3.8 Blood, Plasma and Blood Components
  • 5.3.9 Diagnostic and Laboratory Products
  • 5.3.10 Home Healthcare Supplies
  • 5.3.11 Others
• 5.4 By Delivery Model
  • 5.4.1 B2C
  • 5.4.2 B2B
• 5.5 By End User
  • 5.5.1 Hospitals and Clinics
  • 5.5.2 E-Pharmacies and Pharmacies
  • 5.5.3 Diagnostic Laboratories
  • 5.5.4 Home Healthcare Providers
  • 5.5.5 Direct-to-Patient Deliveries
  • 5.5.6 Others
• 5.6 By Geography
  • 5.6.1 England
  • 5.6.2 Scotland
  • 5.6.3 Wales
  • 5.6.4 Northern Ireland

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Key Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.4.1 Sciensus
  • 6.4.2 Yusen Logistics Group (including Movianto)
  • 6.4.3 Life Couriers UK Limited
  • 6.4.4 Phoenix Healthcare Distribution
  • 6.4.5 AAH Pharmaceuticals
  • 6.4.6 DHL Group
  • 6.4.7 UPS
  • 6.4.8 Oximio
  • 6.4.9 GXO Logistics, Inc.
  • 6.4.10 Royal Mail Group
  • 6.4.11 Polar Speed
  • 6.4.12 CitySprint
  • 6.4.13 Cencora
  • 6.4.14 FedEx
  • 6.4.15 DPDgroup
  • 6.4.16 Uniphar Logistics UK
  • 6.4.17 Geopost
  • 6.4.18 Matternet, Inc.
  • 6.4.19 CEVA Logistics
  • 6.4.20 Kuehne+Nagel
  • 6.4.21 EMED Group
  • 6.4.22 BAP Pharma Limited

7 Market Opportunities and Future Outlook

• 7.1 White-space and Unmet-Need Assessment